IP Library › Granted Patent US 10,836,822
Granted Patent B2
US 10,836,822 · App. 15/923,374 · Granted Nov 17, 2020

Anti-PAR2 antibodies and uses thereof

Inventors: Claire Dobson (Cambridge, GB); Richard Williams (Cambridge, GB); Ian Gurrell (Cambridge, GB); Sadhana Podichetty (Cambridge, GB); David Fairman (Cambridge, GB); Peter Thornton (Cambridge, GB); Philip Newton (Cambridge, GB)
Assignee: MedImmune Limited
C07K16/28A61P29/00A61K2039/505C07K2317/33C07K2317/565C07K2317/622C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,836,822
App. No.
15/923,374
Granted
Nov 17, 2020
Kind
B2
Abstract

The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

Claims (20)

1. An antibody or antigen-binding fragment thereof that binds to PAR2 comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein the VH comprises:

i) a VH-CDR1 having the amino acid sequence of SEQ ID NO: 13,

ii) a VH-CDR2 having the amino acid sequence of SEQ ID NO: 14,

iii) a VH-CDR3 having the amino acid sequence of SEQ ID NO: 15,

and wherein the VL comprises:

i) a VL-CDR1 having the amino acid sequence of SEQ ID NO: 18,

ii) a VL-CDR2 having the amino acid sequence of SEQ ID NO: 19,

iii) a VL-CDR3 having the amino acid sequence of SEQ ID NO: 20.

2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the VH comprises an amino acid sequence that is at least 80%, 85%, 90%, 92%, 93%, 95%, 97%, 99% or 100% identical to SEQ ID NO: 12 and wherein the VL comprises an amino acid sequence that is at least 80%, 85%, 90%, 92%, 93%, 95%, 97%, 99% or 100% identical to SEQ ID NO: 17.

3. The antibody or antigen-binding fragment of claim 1 , wherein the antigen-binding fragment is an scFv or a Fab′.

4. The antibody or antigen-binding fragment of claim 1 , wherein the antibody is a monoclonal antibody.

5. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment prevents trypsin, tryptase and/or matriptase from interacting with PAR2.

6. The antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment binds to PAR2 with greater affinity at a pH of 7.4 than at a pH of 6.0.

7. A composition comprising a pharmaceutically acceptable carrier and the antibody or antigen-binding fragment of claim 1 .

8. A kit comprising the composition of claim 7 .

9. A kit comprising the antibody or antigen-binding fragment of claim 1 .

10. The antibody or antigen-binding fragment of claim 1 , wherein the VH comprises an amino acid sequence corresponding to SEQ ID NO: 12 and wherein the VL comprises an amino acid sequence corresponding to SEQ ID NO: 17.

11. A composition comprising a pharmaceutically acceptable carrier and the antibody or antigen-binding fragment of claim 10 .

12. A method for treating pain in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of the antibody or antigen-binding fragment of claim 10 .

13. A method for treating pain in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of the antibody or antigen-binding fragment of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2018
From: DOBSON, CLAIRE; WILLIAMS, RICHARD; GURRELL, IAN; PODICHETTY, SADHANA; FAIRMAN, DAVID; THORNTON, PETER; NEWTON, PHILIP
To: MEDIMMUNE LIMITED
Reel/Frame 046437/0975 →
Continuity (3)
Provisional Application 62637766 · Mar 2, 2018
Provisional Application 62472462 · Mar 16, 2017
Related Publication 20180305450A1 · Oct 25, 2018